Core Insights - In 2026, China's innovative drug licensing-out transactions are experiencing strong momentum, with 44 licensing events reported by February 25, totaling approximately $31.23 billion in upfront payments and $53.28 billion in total deal value [1] - The trend indicates a shift in China's innovative drug industry from "catching up" to "keeping pace" and even "leading," marking a structural transition from "importing imitation" to "exporting innovation" [1] - The total value of China's innovative drug licensing-out transactions reached a record high of $135.66 billion in 2025, with 157 transactions and $7 billion in upfront payments [1] Group 1 - On January 16, 2026, Xibiman Biotech announced a deal with AstraZeneca for a 50% stake in the development and commercialization rights of C-CAR031 in China [2] - On January 30, 2026, CSPC Pharmaceutical Group signed a strategic R&D cooperation and licensing agreement with AstraZeneca to develop innovative long-acting peptide drugs [2] - On February 8, 2026, Innovent Biologics announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [2] Group 2 - On February 24, 2026, Frontier Biotech announced an exclusive licensing agreement with GlaxoSmithKline (GSK) for two early-stage siRNA products, with an upfront payment of $40 million and potential milestone payments totaling up to $950 million [3] - On February 25, 2026, Dasheng Pharmaceutical announced an exclusive licensing agreement with Slate Medicines for a monoclonal antibody targeting PACAP, excluding Greater China [3] - The overall trend in cross-border cooperation is characterized by faster technological iterations, increased transaction scales, and deeper collaboration models [4] Group 3 - The new collaboration models are evolving from sporadic large projects to a more normalized and platform-based approach, indicating strong industry representation and long-term resilience [4] - Heptares Therapeutics announced a collaboration with Solstice Oncology, including an exclusive licensing and equity cooperation agreement, with an upfront payment exceeding $105 million [5] - The transaction models are shifting from early-stage "selling seedlings" to joint development and regional licensing, reflecting a transition towards quality and value competition in the industry [5]